Vera Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $27,256 | $45,681 |
| Marketable securities | 326,053 | 115,035 |
| Prepaid expenses and other assets, current | 10,822 | 11,307 |
| Total current assets | 364,131 | 172,023 |
| Property and equipment, net | 368 | 92 |
| Operating lease right-of-use assets | 3,921 | 2,949 |
| Prepaid expenses and other assets, noncurrent | 140 | 482 |
| Total assets | $368,560 | $175,546 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,602 | $11,118 |
| Operating lease liabilities | 1,872 | 2,436 |
| Accrued expenses and other liabilities, current | 19,990 | 8,749 |
| Total current liabilities | 26,464 | 22,303 |
| Long-term debt | 50,470 | 49,877 |
| Operating lease liabilities, noncurrent | 2,568 | 1,395 |
| Accrued expenses and other liabilities, noncurrent | — | 286 |
| Total liabilities | 79,502 | 73,861 |
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 10,000,000 authorized as of September 30, 2024 and December 31, 2023; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — |
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 55,026,111 and 44,452,161 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 55 | 44 |
| Additional paid-in capital | 705,784 | 410,492 |
| Accumulated other comprehensive income | 1,044 | 251 |
| Accumulated deficit | (417,825) | (309,102) |
| Total stockholders’ equity | 289,058 | 101,685 |
| Total liabilities and stockholders’ equity | $368,560 | $175,546 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.